ASX-LISTED medicinal cannabis firm Bod Australia has secured its first medicinal cannabis prescription and is entering into a research collaboration agreement with Cannabis Access Clinics and the Biologics Research Institute Australia (BRIA).
The first prescription was for MediCabilis, received from a Cannabis Access Clinics patient.
The collaboration will lead to an observational trial to study the effects of Bod's MediCabilis cannabis oil on "a broad range of patient outcomes", the company said in a statement last week.
Once Bod completes the Phase I Clinical Trial of its sublingual cannabis wafer (PD 25 Jul 2018), it will also be made available through the Cannabis Access network.
Bod CEO Jo Patterson said the agreement also provided the company with a "large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide independent and ongoing feedback around our medicinal cannabis product offering".
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 18
